Acne Vulgaris: Treatment with Azithromycin Kouzeva V, Hitova M, Dancheva A, Kaliasheva P City Center for Dermatovenerology, Sofia Bulgaria.

Slides:



Advertisements
Similar presentations
Table 1 - The scale of Hellegren and Vincent
Advertisements

Dr Stephen Chadwick GPsWI
Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.
ACNE Definition Inflammation of sebaceous follicles Follicle
Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.
Acne Vulgaris between Der. Pts in Palestine By Dr. Hisham Arda, M.D. Ph.D., Associate Prof. AN-Najah Univ. Nablus-Palestine.
Acne Treatment and Therapeutic Strategies
Acne Treatment and Therapeutic Strategies
Pharmacology-4 PHL 425 Seventh Lecture By Abdelkader Ashour, Ph.D. Phone:
Dose-Toxicity Study of Oral Prednisone in Ocular Myasthenia Michael Benatar, Mike McDermott, Gil Wolfe and Don Sanders.
Acne - A physical change in the skin caused by a disease process in the sebaceous follicle - Acne is the term for plugged pores (blackheads and whiteheads),
Different types of drugs treating acne. Diagnosis and Treatment of Acne Acne is a disease of pilosebaceous units in the skin. It is thought to be caused.
 Question: Take a history from May Ling 15 years, examine her face,outline the most likely diagnosis and a management plan.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Back to Medical School 18 th October Acne.
Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Real-World Assessment of Clinical Outcomes in Lower-Risk Myelofibrosis Patients Receiving Treatment with Ruxolitinib Davis KL et al. Proc ASH 2014;Abstract.
Patient reported outcomes: Effectiveness of hormonal treatments for acne Jerry Tan MD, FRCP 1 Karen Y. Fung PhD 2 1 University of Western Ontario and 2.
What’s new?. Acne is a common chronic skin condition which has a significantly negative psychological impact that can be directly improved with treatment.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Mark Dacey MD, Brian Sullivan MD, and Steven Verity MD University of Texas Southwestern Medical Center and VA Medical Center, Dallas, TX None of the authors.
Evalulation of Azelaic Acid for Non-Prescription Use Michelle Brown Andy Reynolds Ted Williams Pharm. D candidates, OSU College of Pharmacy.
Case I A 47 old male presents to your office for a yearly checkup. He smokes 40 cigarette/day, and examination detect wheezy chest and bronchospasm. His.
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
1 FDA Perspective on Global Evaluation of Facial Acne Brenda Carr, M.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
Objectives What is acne? Pathogenesis. Acne lesion. Classification. Clinical variant of acne. What makes acne worse? Differential Diagnosis. Diagnosis.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Presented By Michael Overman at 2016 ASCO Annual Meeting
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
Acne Vulgaris Prepared by: Dr. Murtadha Hashim Raheem MBChB;FICMS بورد ( دكتوراه ) اختصاص الامراض الجلديةوالتناسلية
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
The Stages of a Clinical Trial
A New Anti-inflammatory Therapy For COPD
Gerova V., V. Nakov, L. Tankova, P. Penchev, R. Nakov
Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust
Seema Jain1, Rebecca Andridge2, Jessica Hellings3
ACNE VULGARIS -Nisarg Kothari.
Acne Vulgaris TSMU.
Acne vulgaris moderate. A
Dr. Abdulaziz Saeedan PhD, Pharmacology
The ASSERT Study.
Acne Vulgaris Dr. M.Ebrahim zadeh
Evaluate the results of concomitance chemoradiotherapy postoperative treatment for rectal cancer in stage II-III At K Hospital from 2012 to 2016 Speaker:
Krop I et al. SABCS 2009;Abstract 5090.
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
LAB REPORT (50 pts) I- Title (1)
Updates on Anti-VEGF Therapy: Improving Durability and Predicting Response.
Section 7: Aggressive vs moderate approach to lipid lowering
Comparison of NNRTI vs PI/r
Major classes of drugs to reduce lipids
Alison Barton Dermatology Specialist Nurse
2. DEVELOPMENT OF OBJECTIVE
2. DEVELOPMENT OF OBJECTIVE
Presentation transcript:

Acne Vulgaris: Treatment with Azithromycin Kouzeva V, Hitova M, Dancheva A, Kaliasheva P City Center for Dermatovenerology, Sofia Bulgaria

INTRODUCTION I Acne Vulgaris is multifactor disease and there are lot of target places for therapeutic alleviation. The typical pathogenesis development of the disease is abnormal follicular keratinisation of the pilosebaceic unit, followed by sebum accumulation, which leads to the first lesions in acne: comedons. The colonization of Propionbacterium acnes in the comedons and the the followed inflammation, leads to lesions of which papules and pustules are features of the moderate acne papulopustulosis..

INTRODUCTION II Acne is not infectious disease, but the antibiotics have a major place in the therapeutic approaches of the treatment. Mechanisms of action of antibiotics against Acne are two: Reduction of the quantity of P.acnes and subsequent change of the ratio between free lipid acids compared to superficial lipids; Reduction of the free lipid acids trough inhibition of the bacterial lipases. The antibiotics used for the treatment of acne are requiring frequently dosing and are related to unwanted side effects.

METHODS I 1.PATIENT CHARACTERISTICS: NumberPercent of total Patients Nr % Male % Female % Age 12 –25 2.Treatment and dosing regimen: 3 times weekly -250mg of Azythromycin for 10 weeks.

 Moderate to severe acne papulopustulosis, with number of the lesions varying from 10 to 50, spread in the face, back and neck.  Patients should not be treated with antibiotics for acne therapy for the last 4 weeks.  Patients should not be treated with hormonal preparations for acne therapy for the last 3 months.  Patients should not be treated with topical anti-acne therapy for the last 4 weeks. METHODS II 3. Inclusion criteria:

METHODS III 4. Distribution of the patients, depending on the severity of Acne: Number of papulopustulosis Patients number Percent of the total % 20 – % 30 – % 40 – %

METHODS IV 5. Visits during the 24 weeks observation period: Visit 1 – Initial visit for the start of the therapy Visit 2 - on week 3 Visit 3 - on week 10 Visit 4 - on week 24 During the course of the treatment patients used topical non-comedonogenic dermatocosmetics.

 Reduction of the number of the lesions in the face,back and neck.  Patients subjective assessment for the therapeutic alleviation of acne. METHODS V 6. Criteria for evaluation of the treatment efficacy:

RESULTS I Patients number Percent Reduction of the number of the lesions % Reduction over 80% male % Reduction over 80% female % Reduction over 80% TOTAL % Reduction below 25% male % Reduction below 25% female % Reduction below 25% TOTAL % Evaluation on week 3 by Investigator

RESULTS II Patients number Percent Evaluation by the patients % Full treatment success % Very good improvement % Satisfactory improvement % Lack of improvement 00% Deterioration 00% Evaluation on week 3 by Patients

RESULTS III Patients number Percent Reduction of the number of the lesions % Reduction over 80% TOTAL % Reduction below 25% TOTAL % Evaluation on week 10 by Investigator

RESULTS IV Patients number Percent Evaluation by the patients % Full treatment success % Very good improvement % Satisfactory improvement 63.7% Lack of improvement 00% Deterioration 00% Evaluation on week 10 by Patients

RESULTS V Patients number Percent Reduction of the number of the lesions % Reduction over 80% TOTAL % Reduction below 25% TOTAL % Evaluation on week 24 by Investigator

RESULTS VI Patients number Percent Evaluation by the patients % Full treatment success % Very good improvement % Satisfactory improvement % Lack of improvement 63.7% Deterioration 63.7% Evaluation on week 24 by Patients

RESULTS VII DURING 10 WEEKS OF TREATMENT WERE NOT OBSERVED UNWANTED SIDE EFFECTS RELATED TO AZITHROMYCIN

 The results drawn by the study are showing the high efficacy of azithromycin in the treatment of Acne papulopustulosis.  Azithromycin is safe and well tolerated in real clinical settings.  Azithromycin is convenient for application – 1capsule of 250mg, 3 times a week for 10 weeks. CONCLUSIONS